HeartBeam, a medical technology company focused on advanced cardiac care, announced that its management team will participate in several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging.
In addition, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology’s annual scientific conference on March 28-30. At this event, the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. The company’s news and updates are available in its newsroom at https://ibn.fm/BEAT.
This series of presentations is significant because it provides a platform for HeartBeam to demonstrate its pioneering cardiac monitoring technology to key stakeholders in both the investment and medical communities. The company is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable use wherever a patient is located, aiming to deliver actionable heart intelligence outside traditional medical facilities.
The potential impact of this technology is substantial for patients, healthcare providers, and the broader medical technology industry. For patients, it could enable earlier detection and continuous monitoring of cardiac conditions like arrhythmias without requiring frequent hospital visits, potentially improving outcomes and quality of life. For physicians, the system promises to help identify cardiac health trends and acute conditions, directing patients to appropriate care remotely. For the industry, HeartBeam’s approach represents a shift toward more accessible, data-driven cardiac care models.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software was cleared in December 2025. The company holds over 20 issued patents related to its technology. However, as with any forward-looking statements, actual results may differ due to various risks and uncertainties. Full terms of use and disclaimers applicable to content are available at http://IBN.fm/Disclaimer.
By engaging with investors at conferences like Oppenheimer and ROTH, and with medical professionals at ACC.26, HeartBeam is positioning its technology as a tool that could redefine cardiac health management. The demonstrations of its extended wear patch prototype are particularly noteworthy, as they signal progress toward making continuous, clinical-grade ECG monitoring more practical for everyday use. This could address a critical gap in cardiac care, where many conditions go undetected until a serious event occurs, by enabling proactive, remote monitoring that integrates into patients’ daily lives.
